Randomized Trialvery high evidence
Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England journal of medicine·March 6, 2025·PMID 39536238
Why it mattersThis provides the longest-term efficacy and safety data for tirzepatide in obesity with prediabetes, demonstrating sustained weight loss and a 93% relative risk reduction in progression to type 2 diabetes over 3 years. It supports tirzepatide as a disease-modifying intervention in high-risk patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled